Zhejiang Taimei Medical Technology Co., Ltd. Stocks

HK$ 4.66Last Updated 15.04.2026

Issuer Rating

3/7
Performance

Average

Risk

High

Recommendation

Sell

Market Cap

HK$ 338.47M

Buy
Review
Evaluation
Target price
Dynamics
Performance
Growth
Dividends
Risks
HK$ 4.66
Key Takeaways

Risk factor

Very high price volatility

Data is available to registered users only
Data is available to registered users only

Profitability factor

Favourable analyst view

Data is available to registered users only
Data is available to registered users only
Sign up to get free access to key risk and return factors, detailed company valuation, and analyst forecasts
Sign up to access all the key risk and return factors

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

About

Zhejiang Taimei Medical Technology Co., Ltd. provides digital operation platform for the biopharma industry in China. The company offers TrialOS, a drug digital cooperation platform that connects the cycle of hospitals, pharmaceutical companies, third-party providers, regulatory authorities, patients, and other industry stakeholders. It offers software solutions, such as eCooperate, a clinical trial cooperation platform that optimizes clinical research operations management systems, as well as support decision-making with big data technology; eArchives, a clinical trial master file system; eCollect, an electronic data capture system; eCollege, a training management system; eQuality, an electronic quality audit system; eBalance, an interactive Web-based response system; eVisit Patient Reported Outcomes, a solution that enhances the ability of patients to enter data and the accuracy of clinical trial data; eTime, a project man-hour management system; and eImage, a medical image reading system. It also provides hospital software, including eTrial, a phase I ward management system; eSite, a clinical trial management system for GCP sites; GCP-X, an intelligent clinical trial platform; NomenCTMS, a clinical research project management system for GCP sites; eScreening, a subject information management and duplicate checking system; Intelligent Investigator, an initiated clinical trial platform; IIT-EDC, a clinical research data management platform; and Investigator-Initiated Clinical Trial Management System, a project management system. In addition, the company offers pharmacovigilance software solutions, such as eSafety global pharmacovigilance system; eSafety, an intelligent professional information system for pharmacovigilance; and SAE Manager, a safety data communication and management system for clinical trials. Further, it provides marketing software and digital innovation solutions. The company was founded in 2013 and is headquartered in Jiaxing, China.

Company Valuation

Fairly valued
4/7

From both historical and forecast perspectives, the stock is fairly priced compared to similar stocks. Specifically, the stock is fairly valued on P/E, undervalued on EV/

Data is available to registered users only
Sign up to access detailed valuation

Target Price

Favourable
6/7

The average target price of 2576.HK is 6.7 and suggests 44% upside potential. Usually, this means a BUY recommendation among investment firms, or a recommendation to incr

Data is available to registered users only
Sign up to access analyst forecasts

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis
X-channel

Buy

Sell

0 more stocks